Clinical Development in Challenging Cancers: Cholangiocarcinoma (CCA)
Date posted: June 28, 2018
In the final installment of this four-part series on the Clinical Development in Challenging Cancers, our Medics take a closer look at the developing treatments and therapeutic challenges of Cholangiocarcinoma (CCA):
“CCA is considered to be the second most frequent primary hepatobiliary malignancy after hepatocellular carcinoma (HCC)4. Due to the uneven distribution of risk factors, incidence rates are varying intra- and intercontinentally, with the lowest rates in Australia and the highest rates in Southeast Asia, where annual incidence rates can reach up to 71.3/100,0005.”
We invite you to read the entire article (pages 40-43) in Journal for Clinical Studies by clicking at the cover image.